CDTX - Cidara Therapeutics - Stock Forecast

Healthcare - Sector
Coverage Stock analysts Price Targets & Ratings Chart Insider Trading

CDTX is currently covered by 4 analysts with an average price target of $39.21. This is a potential upside of $16.37 (71.67%) from yesterday's end of day stock price of $22.84.

Cidara Therapeutics's activity chart (see below) currently has 9 price targets and 37 ratings on display. The stock rating distribution of CDTX is 100% BUY.

Stock Analyst Price Targets - Review

Analysts average stock forecasts to be materialized ratio is 23.31% with an average time for these price targets to be met of 50.8 days.

Highest price target for CDTX is $36, Lowest price target is $35, average price target is $35.5.

Most recent stock forecast was given by JOSEPH STRINGER from NEEDHAM on 04-Jun-2025. First documented stock forecast 11-May-2015.

Currently out of the existing stock ratings of CDTX, 26 are a BUY (100%).

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Buy

$36

$13.16 (57.62%)

$35

10 days ago
(04-Jun-2025)

3/7 (42.86%)

$11.95 (49.69%)

205

Buy

$35

$12.16 (53.24%)

$24

3 months 4 days ago
(10-Mar-2025)

4/17 (23.53%)

$12.61 (56.32%)

91

Buy

10 months ago
(14-Aug-2024)

0/2 (0%)

$-15.8 (-75.96%)

Buy

3 years 2 months 1 days ago
(14-Apr-2022)

1/1 (100%)

$-2.15 (-14.19%)

158

Buy

$8

3 years 2 months 1 days ago
(14-Apr-2022)

0/3 (0%)

$6.41 (284.34%)

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What is CDTX (Cidara Therapeutics) average time for price targets to be met?

On average it took 50.8 days on average for the stock forecasts to be realized with a an average price target met ratio 23.31

Which analyst has the current highest performing score on CDTX (Cidara Therapeutics) with a proven track record?

JOSEPH STRINGER

Which analyst has the most public recommendations on CDTX (Cidara Therapeutics)?

Joseph Stringer works at NEEDHAM and has 3 price targets and 5 ratings on CDTX

Which analyst is the currently most bullish on CDTX (Cidara Therapeutics)?

Robert Driscoll with highest potential upside - $76.06

Which analyst is the currently most reserved on CDTX (Cidara Therapeutics)?

David Nierengarten with lowest potential downside - -$0

Cidara Therapeutics in the News

Cidara Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results

Data cutoff date for Phase 2b NAVIGATE trial efficacy reached on April 30, 2025; top-line data readout expected in late June 2025Nature Microbiology publication highlights preclinical data and the potential of CD388 as a potent, universal antiviral for influenza prevention in healthy and high-risk populations regardless of immune statusConference call and webcast today at 5:00...

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?